We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) ended the recent trading session at $53.78, demonstrating a +1.34% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 9.52%. Meanwhile, the Dow gained 7.87%, and the Nasdaq, a tech-heavy index, added 12.16%.
The biopharmaceutical company's stock has dropped by 13.72% in the past month, exceeding the Medical sector's loss of 14.16% and lagging the S&P 500's loss of 13.47%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. The company's earnings report is expected on April 24, 2025. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.55 per share. This would mark year-over-year growth of 135.23%. Alongside, our most recent consensus estimate is anticipating revenue of $10.69 billion, indicating a 9.94% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $6.75 per share and a revenue of $45.59 billion, demonstrating changes of +486.96% and -5.6%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Currently, Bristol Myers Squibb is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Bristol Myers Squibb is presently trading at a Forward P/E ratio of 7.86. This expresses a discount compared to the average Forward P/E of 15.86 of its industry.
We can additionally observe that BMY currently boasts a PEG ratio of 1.97. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.31.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today
Bristol Myers Squibb (BMY - Free Report) ended the recent trading session at $53.78, demonstrating a +1.34% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 9.52%. Meanwhile, the Dow gained 7.87%, and the Nasdaq, a tech-heavy index, added 12.16%.
The biopharmaceutical company's stock has dropped by 13.72% in the past month, exceeding the Medical sector's loss of 14.16% and lagging the S&P 500's loss of 13.47%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. The company's earnings report is expected on April 24, 2025. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.55 per share. This would mark year-over-year growth of 135.23%. Alongside, our most recent consensus estimate is anticipating revenue of $10.69 billion, indicating a 9.94% downward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $6.75 per share and a revenue of $45.59 billion, demonstrating changes of +486.96% and -5.6%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.02% higher. Currently, Bristol Myers Squibb is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Bristol Myers Squibb is presently trading at a Forward P/E ratio of 7.86. This expresses a discount compared to the average Forward P/E of 15.86 of its industry.
We can additionally observe that BMY currently boasts a PEG ratio of 1.97. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.31.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.